Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. by Eliason, J. F. et al.
Br. J. Cancer (1993), 67, 1293-1298
(.) Macmillan
Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer
cell lines in vitro
J.F. Eliason, F. Kaufmann (posthumous), T. Tanaka & T. Tsukaguchi
F. Hoffmann-La Roche A.G., Pharmaceutical Research, CH-4002 Basle, Switzerland; Nippon Roche Research Center, Department
ofOncology, 200 Kajiwara, Kamakura 247, Japan.
Summary A novel arotinoid with a morpholine structure in the polar end group Ro 40-8757 (4-[2-[p-[(E)-
2(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]phenoxy]ethyl]-morpholine) was tested for its
anti-proliferative activity against nine human cancer cell lines in vitro. The lines included two estrogen receptor
positive breast cancer lines (MCF-7 and ZR-75-1), two estrogen receptor negative breast cancer lines
(MDA-MB-231 and BT-20), one cervix carcinoma line (KB-3-1), two lung adenocarcinoma lines (A549 and
HLC-1), one large cell lung cancer line (LXFL 529) and two colorectal lines (CXF 243 and CXF 280).
Proliferation of all the lines, except the two lung adenocarcinoma lines, was inhibited by lower concentrations
of Ro 40-8757 than those of all-trans retinoic acid (RA) or 13-cis RA giving the same level of inhibition. The
degree of inhibition of RO 40-8757 was concentration and time dependent. The arotinoid was not cytotoxic
and morphological signs by differentiation were not evident in cultures treated with Ro 40-8757 for up to 2
weeks. Because this compound is active on cells such as KB-3-1 that are not inhibited by all-trans RA and
because it does not bind to nuclear retinoic acid receptors, it may represent a novel class of anti-proliferative
agents.
It has long been known from many studies that retinoids can
inhibit growth in vitro ofcertain types of cancer cells and can
prevent tumour formation in some animal models (Lippman
et al., 1987a). Until recently, despite a number of clinical
trials in various indications (Lippman et al., 1987b),
retionoids have not found widespread usage for treatment of
cancer. The demonstration by several groups that all-trans
retinoic acid (RA) can induce complete remission in a high
proportion of acute promyelocytic leukaemia patients
(Huang et al., 1988; Chomienne et al., 1989; Warrell et al.,
1991) has renewed clinical interest. It has also been demon-
strated that one of the isomers of all-trans RA, 13-cis RA,
can significantly inhibit the formation of second cancers in
head and neck carcinoma (Hong et al., 1990). Recent clinical
reports indicate that the combination of 13-cis RA plus
interferon a is highly effective in advanced squamous cell
carcinomas of the cervix (Lippman et al., 1992a) and skin
(Lippman et al., 1992b).
In searching for a retinoic acid analog that might be
devoid of some of the side effects associated with hyper-
vitaminosis A syndrome, the arotinoid temarotene (Ro 15-
0778), which has an unusual structure because it lacks a
polar end group, was shown to be active both in preventing
tumour formation in rats given DMBA (Bollag & Hartmann,
1987) and in inducing regression of established mammary
carcinomas in these animals (Teelmann & Bollag, 1988). A
number of analogs of temarotene have been synthesised to
find a more potent compound for therapeutic use. The most
active compound identified thus far is Ro 40-8757, an
arotinoid containing a morpholine structure in the polar end
group (4-[2-[p-[(E)-2(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthyl)propenyl]phenoxy]ethyl]-morpholine). This com-
pound has considerable anti-tumour activity against estab-
lished mammary tumours in rats (Eliason et al., 1990b; Hart-
mann et al., 1992).
We have examined the ability of Ro 40-8757 to inhibit
proliferation ofhuman cancer cells in vitro. Nine different cell
lines have been used for these studies: two breast cancer lines
expressing estrogen receptors (MCF-7 and ZR-75-1), two
breast cancer lines that do not express estrogen receptors
(BT-20 and MDA-MB-231), two lung adenocarcinoma lines
(A549 and HLC-1), one large cell lung cancer line (LXFL
529) and two colorectal carcinoma lines (CXF 243 and CXF
280). The results have also been compared to those obtained
using all-trans RA and 13-cis RA.
Materials and methods
Cell lines
The human breast cancer cell lines, ZR-75-1, MDA-MB-231
and MCF-7 were obtained from ATCC and BT-20 was
obtained from Prof. Eppenberger (University of Basel,
Switzerland). The line KB-3-1 was obtained from Dr M.M.
Gottesman (N.C.I., U.S.A.) and originates from the human
cervical cancer cell line HeLa. The lung cancer lines HLC-1
and A549 were obtained from ATCC. The large cell lung
carcinoma line, LXFL 529, and the two colon carcinoma
lines, CXF 243 and CXF 280, were purchased as xenograft
lines from Dr H.H. Fiebig (University of Freiburg, Ger-
many). They were adapted for tissue culture in our
laboratory and were used between passages 11 and 20 after
explantation. The LXFL 529 line grew in vitro with a doubl-
ing time of 118 ± 30 h, the CXF 280 line with a 52 ± 14 h
doubling time and CXF 243 with a doubling time of
49 ± 27 h.
Retinoids
Stock solutions of all-trans RA and 13-cis RA were prepared
under subdued lighting in dimethyl sulfoxide (DMSO) at a
concentration of 6 x 10-2 M. The arotinoid Ro 40-8757 was
dissolved in DMSO to give a stock solution of 2 x 10-2 M.
These solutions were stored at - 80'C in the dark and were
diluted in culture medium just before use.
Cellproliferation assay
Cells were cultured in RPMI 1640 nutrient medium (Gibco,
UK) supplemented with 10% foetal calf serum (FCS; Gibco).
They were seeded into 24 well tissue culture plates (Costar)
and incubated for 24 h before drugs were added to ensure
attachment of the cells. The culture medium and test sub-
stances were refreshed every 2-3 days. The total culture time
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was approximately 14 days. Cells were harvested from four
replicate wells per group each time the cultures were refed.
Viable, trypan blue excluding cells were counted using a
hemocytometer.
MTTassay
The colorimetric assay for viable cell numbers was performed
essentially as described previously (Eliason et al., 1990a).
Cells were cultured in EF medium prepared as described
(Eliason, 1984; Eliason et al., 1984) and supplemented with
5% FCS. Aliquots of 100 lI of the cell suspensions were
plated in 96 well microtiter plates (Falcon-Becton Dickinson,
USA) and incubated for 24 h at 37°C in a fully humidified
atmosphere of 5% Co2 in air before addition of drugs. In
order to correct for the non-linearity of the MTT assay with
respect to cell numbers (Plumb et al., 1989), a control cell
titration curve was included in each assay (Eliason et al.,
1990a).
The drugs were added in 100ftl of medium containing
0.1% of DMSO to wells in which the highest cell concentra-
tion was plated. The optimal cell concentration for each cell
line was determined in preliminary studies. For MCF-7 and
ZR-75-1, the highest cell concentration used was 800 cells
well-'. For MDA-MB-231, 200 cells well-' were plated. For
BT-20, LXFL 529 and CXF 243, the optimal concentration
was 2400 cells well-' and for CXF 280, 1200 cells well-' were
plated. Every 2 or 3 days, a portion of the medium (100yIl)
was removed from the wells and a 2-fold concentrated solu-
tion of fresh drug was added in the same volume of medium.
After a total of 10 days incubation, 501gl of a 3mgml-'
solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) was added. The HLC-1 and A549
lines grew much faster, so that the maximum numbers of
cells plated were 300 and 200 cells well-', respectively. The
maximum duration of incubation for these two lines was
only 4 days and 5 days, respectively.
The cells were incubated with MTT for 6 h at 37°C after
which time, 50f1 of a 25% (w/v) solution of sodium dodecyl
sulfate (SDS) with a pH of 2.0 was added. The plates were
incubated overnight to dissolve the formazan crystals and
then the absorbance at 540 nm was measured using a micro-
plate reader (Bio-rad, model 3550).
The relationship between log cell number and log absorb-
ance was determined by least squares regression analysis and
this was used to relate the absorbance measured in the drug
treated groups to number of cells as has been described
(Eliason et al., 1990a). Regression lines for logit percent
survival vs log drug concentration were used to calculate the
doses of compounds resulting in a 50% reduction in cell
numbers compared to control cultures (IC50).
Cell cycle analysis
Two treatment protocols were used to examine the effect of
Ro 40-8757 on cell cycle parameters. In the first experiment,
ZR-75-1 cells were suspended in EF medium containing 5%
FCS at a concentration of 1 x I05 cells ml-' and 5 ml ali-
quots were seeded in T-25 tissue culture flasks (Falcon-
Becton Dickinson, USA). The cells were incubated at 37°C
for 5 days, at which time, the medium was removed, and
replaced with fresh medium containing 1 x 10-6M Ro 40-
8757 or with fresh medium alone (controls). The cells were
incubated for 1 more day and then harvested using typsin-
EDTA solution. In the second experiment, the same concen-
tration of cells was plated 1 day before medium removal and
treatment with Ro 40-8757.
After harvesting, the cells were stained with propidium
iodide according to the instructions supplied with the test kit
(CycleTEST DNA Reagent Kit; Becton Dickenson Immuno-
cytometry Systems USA). The cell cycle parameters were
analysed using an Epics C flow cytometer (Coulter Elec-
tronics, Hialeah FL, USA). The proportions of cells in
Go + G,, S and G2 + M were determined by the PARAl
program supplied by Coulter.
Clonogenic assay
A methylcellulose based medium was used to assay the effect
of all-trans RA and Ro 40-8757 on colony formation by
HLC-1 and A549 cells (Eliason et al., 1984; 1985). The
methylcellulose concentration was 0.9% in EF medium sup-
plemented with 5% FCS. The drugs were added to the plates
after 1 day of incubation at 37°C. Fresh drug was added on
days 4 and 6. Colonies with greater than approximately 50
cells were counted after a total incubation time of 8 days.
Statistical evaluation
Results are expressed as mean of three or four replicates. The
standard deviations were typically less than 10% in individ-
ual experiments and thus are not depicted. Where error bars
are shown, they refer to standard errors for mean results
from multiple experiments. Differences between means were
tested using Student's t-test with P values less than 0.05
being considered statistically significant.
Results
The effect of Ro 40-8757 on cell proliferation has been
examined by counting viable cells after various periods of
treatment. The arotinoid did not decrease the numbers of
cells, but did slow down the rate of proliferation. The non-
cytotoxic nature of this compound is also reflected by the
fact that the proportion of viable cells in all treatment groups
in at least 17 experiments was always greater than 90%
throughout 14 days of treatment. The highest dose of
arotinoid tested in these experiments was 3J1M. The results of
representative experiments with the breast cancer lines BT-20
and ZR-75-1 are shown in Figure 1 (a and b). Inhibition of
the rate of proliferation, as indicated by expression of the
results as percentage of cell numbers in control cultures,
occurred in a dose and time dependent manner. The
inhibitory effects of the arotinoid increased during the first
13-15 days. Ro 40-8757 also inhibited growth of the KB-3-1
line, which proliferates more rapidly then the breast cancer
lines and maximal inhibition appeared to be reached by day
9 (Figure 1).
The effect of Ro 40-8757 on cell cycle parameters of
ZR-75-1 and MCF-7 cells was examined after 24 or 48 h
incubation with the arotinoid by staining the DNA with
propidium iodide and analysing using a flow cytometer. The
results are shown in Table I. Both cell lines showed a clear
decrease in cells in S-phase following 24 h of treatment. In
the ZR-75-1 line, this was accompanied by an increase of
cells in Go and G,. After 48 h treatment, the increase was
shifted to the G2 plus M peak. No increase in proportion of
cells in the Go- and GI-phases were detected with MCF-7
cells at either time point, whereas there was an increase in
G2- plus M-phase cells after 24 h of treatment.
Figure 2 shows a comparison of the dose-response curves
for Ro 40-8757 and two retinoic acid isomers, all-trans RA
and 13-cis RA, with the three cell lines. The two breast
cancer lines show quite different sensitivities to retinoic acids.
The estrogen receptor negative line BT-20 was inhibited only
at RA concentrations above 3 x 10-6 M. Growth of the est-
rogen receptor positive ZR-75-1 line, on the other hand, was
inhibited to more than 60% at the lowest dose tested, 1 x
10-6 M. There was no difference in activity between the two
retinoic acid isomers with either of these breast cancer lines.
The cervical carcinoma line KB-3-1 was not responsive to
treatment with 13-cis RA, whereas its growth appeared to be
slightly stimulated by treatment with all-trans RA at concen-
trations between 1 x 10' and I x 10-6M. The inhibitory
effects of Ro 40-8757 were much greater than those seen with
either of the retinoic acids and were approximately the same
for all three cell lines, about 40% inhibition at a dose of 3 x
10-8 M in this experiment.
The Ro 40-8757 IC50 values for three different breast
cancer cell lines were determined from dose-response studiesANTI-PROLIFERATIVE ACTIVITY OF Ro40-8757 1295
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Figure 1 Time dependency of the anti-proliferative effect of Ro 40-8757 on BT-20 a, and ZR-75-1 b, breast cancer cells and
KB-3-1 cervical cancer cells c. The cells were plated at a concentration of I x 104 cells ml-I (panel a and b) or I x 103 cells ml-'
(panel c) in the presence of various concentrations of Ro 40-8757. The results are expressed as percent of control (vehicle alone)
numbers of viable cells counted on days 3 (open circles), 6 (closed circles), 9 (open triangles), 13 c or 14 (a and b; closed triangles)
or 15 (open squares).
Table I Effect of Ro 40-8757 on cell cycle parameters of human breast cancer cell lines
Experiment Cell line Treatment time (h) Addition GI + Go S G2 + M
ZR-75-1 24 medium 73 26 1
Ro 40-8757 82 15 3
2. ZR-75-1 24 medium 64 21 15
Ro 40-8757 80 17 3
48 medium 71 27 2
Ro 40-8757 69 19 12
MCF-7 24 medium 62 34 4
Ro 40-8757 64 16 20
48 medium 57 31 12
Ro 40-8757 63 26 11
a b c
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Figure 2 Comparison of the dose-response curves for Ro 40-8757 (solid bars), all-trans RA (hatched bars) and 13-cis RA (open
bars) with BT-20 a, ZR-75-1 b and KB-3-1 c cells. Cells were plated as described in Figure 1. Viable cells were counted on day 12
and results are expressed as a percentage of cell numbers in control wells.
using an indirect colorimetric assay for viable cell numbers
(Table II). These values indicate that the MDA-MB-231 line
is the most sensitive to inhibition by the arotinoid. The
ZR-75-1 line is the least sensitive and MCF-7 has inter-
mediate sensitivity.
The anti-proliferative activities of Ro 40-8757, all-trans RA
and 13-cis RA have also been examined using the MTT assay
with 3 lung cancer cell lines. Two of the lines, the adenocar-
cinoma lines A549 and HLC-1, are widely used and have ben
passage many time in vitro before assay. The third line,
a
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Table II Inhibitory activity of Ro 40-8757 on human breast cancer
cell lines in an MTT assay
Number of
Cell line IC50 ± s.e.m. experiments
MDA-MB-231 1.2 ± 0.6 x 10-7M 7
MCF-7 3.8±0.5x10-7M 15
ZR-75-1 9.4±2.8x10-7M 15
120
100
0
LL
L)
Figure 3 Comparison of the IC50 values for all-trans RA, 13-cis
RA and Ro 40-8757 obtained with three lung cancer cell lines.
The results show the mean values obtained from 2-6 (n) indepen-
dent experiments using the MTT assay. Solid bars represent
results for Ro 40-8757, hatched bars for all-trans RA treated
cells, for open bars 13-cis RA. Vertical bars represent standard
errors of the mean. Asterisks represent P values <0.05 compared
to all-trans RA. Crosses represent P values <0.05 compared to
13-cis RA.
LXFL 529, is derived from a lung large cell carcinoma
xenograft line and was recently adapted to growth in vitro.
The results showing the mean IC,0 values from several
independent experiments are shown in Figure 3. The IC50s
for the two retinoic acid isomers as well as for Ro 40-8757
were similar for the rapidly growing adenocarcinoma lines.
The assay times for these two lines in the MTT assay system
were shorter than for the other lines used in these studies
because of their rapid growth rate. Therefore they were also
assayed in a clonogenic assay employing 7 days of incubation
with the compounds. The results are summarised in Table
III. The arotinoid had no effect on colony formation by
either cell line at concentrations up to 1 x 10-6 M. All-trans
RA at the highest dose inhibited colony numbers formed by
both cell lines by 20-25%, but these differences were not
statistically significant.
The large cell lung line, LXFL 529, had an unusual pattern
of reactivity to the retinoic acid isomers. It was significantly
less sensitive to 13-cis RA than it was to all-trans RA. The
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Figure 4 Comparison of the IC50 values for Ro 40-8757, all-trans
RA and 13-cis RA obtained with two colorectal cancer cell lines.
Symbols are as described in the legend to Figure 3.
arotinoid was significantly more active (IC50 = 3.9 ± 0.6 x
10-6 M) than either retinoic acid, being 4-fold more potent
than all-trans RA and 24-fold more active than 13-cis RA.
The two colorectal cell lines were very sensitive to the
growth inhibiting effects of the retinoic acids (Figure 4). The
mean ICm values were between 3 x 107 M and 5 x 10-7 M.
There were no significant differences between the two isomers
in activity. Both lines were significantly more sensitive to Ro
40-8757 than to all-trans RA or 13-cis RA. The CXF 243 line
was the most sensitive, with a mean IC50 of 6 x 10-8 M.
Discussion
The arotinoid Ro 40-8757 was initially identified as a poten-
tial anticancer compound because of its activity against
chemically induced rat mammary cancers (Eliason et al.,
1990b; Hartmann et al., 1992). The results of this study
demonstrate that it also has direct anti-proliferative activity
in vitro against four different human breast cancer cell lines
in vitro as well as against a lung large cell carcinoma line and
two colorectal cancer cell lines.
This arotinoid inhibited cell growth, but was not directly
cytotoxic. Furthermore, there appeared to be no specific
block in cell cycle in the two breast cancer lines examined.
These aspects of the activity of Ro 40-8757 appear to be
similar to the results found with many cell lines treated with
all-trans RA and other retinoids in vitro (Lippman et al.,
1987a). However, the anti-neoplastic effects of all-trans RA
in acute promyelocytic leukaemia are the result of inducing
the leukaemic cells to differentiate into terminally
differentiated mature cells (Castaigne et al., 1990), and we
have no evidence that Ro 40-8757 induces cell differentiation
in the lines we have examined, at least at the level of observa-
tion using light microscopy.
Table III Effect of all-trans RA and Ro 40-8757 on colony formation by A549 and HCL-1 lung cancer cells
Mean colonies/IlO cells ± s.e.m.
Cell line Compound Control 10J-Im JO-,OM 10 9M 10-8M 10-7M 10-6M
A549 all-trans RA 126± 17 163±26 170± 14 179± 18 149±25 149±34 93± 17
A549 Ro 40-8757 154±12 142±11 134±16 135±15 154±16 151±15 166±22
HLC-1 all-trans RA 364± 37 356±20 341 ± 12 309 ± 21 314±7 307 ± 18 281 ± 45
HLC-1 Ro 40-8757 282 ± 9 309 ± 19 264 ± 25 366 ± 43 351 ± 45 325 ± 7 369 ± 28ANTI-PROLIFERATIVE ACTIVITY OF Ro40-8757 1297
The anti-proliferative activity of Ro 40-8757 was fully
apparent only after extended periods of incubation up to 1
week or more. Other agents that have similar time courses
are often ligands for nuclear receptors such as the retinoids,
vitamin D, thyroid hormone, and the steroid hormones.
Biological modifiers like the interferons also act in this way.
The delay in measurable effect with these agents is due to the
fact that they specifically stimulate new gene expression and
thereby cause changes in cellular phenotypes.
The basic chemical structure of Ro 40-8757 is related to
the arotinoid analogs of retinoic acid. However, because it
does not have an acidic group, it does not bind to the
nuclear retinoic acid receptors (Crettaz et al., 1990, Eliason et
al., 1990b). Furthermore, it does not activate transcription in
a trans-activation assay using a reporter gene with a retinoic
acid responsive element and it is inactive in many functional
assays in which all-trans RA is highly active, such as induc-
tion of differentiation by HL-60 leukaemia cells and reduc-
tion of chemically induced skin papilloma size in mice
(Eliason et al., 1990b).
If the growth inhibitory effects of Ro 40-8757 are mediated
by a metabolite that binds to and activates the RA receptors,
then it would be expected that the parent compound should
have a lower activity in vitro than all-trans RA, because few
of the synthetic retinoids that have been tested for receptor
binding have higher affinities than this physiological ligand
(Crettaz et al., 1990; Eliason et al., 1990b). However, in most
of the cell lines examined, the arotinoid inhibited prolifera-
tion at considerably lower concentrations than did all-trans
RA. This difference was greatest in the lines BT-20, CXF 243
and, in particular, KB-3-1. Taken together our results suggest
that the anti-proliferative activity of Ro 40-8757 may be
mediated through a mechanism that does not involve the RA
receptors.
Interestingly, 13-cis RA has a similar anti-proliferative
activity to that of all-trans RA in all of the lines except the
large cell lung carcinoma line (LXFL 529). Chomienne et al.
(1990) have reported that 13-cis RA is also less potent than
all-trans RA for inducing differentiation of blast cells from
patients in vitro. The affinity of the cis isomer for binding to
RA receptors is significantly weaker than that of all-trans RA
by about 5- to 10-fold (Crettaz et al., 1990; Eliason et al.,
1990b). This implies that all-trans RA should be the more
active isomer in most tests as it is with LXFL 529 and acute
promyelocytic leukaemia cells. However, the fact that the two
isomers have nearly identical activities with many cell lines
indicates that these cells can isomerise the cis form to the
trans configuration and that the few cell types that do not
show this equivalence of activity may lack this isomerase
activity.
The arotinoid was much less active against the two long
established lung adenocarcinoma lines than it was against the
other cancer cell lines examined in these studies. This lack of
activity was not merely due to the shorter incubation times
resulting from the more rapid proliferation rate of these cells,
because it was also not active in the clonogenic assay em-
ploying a longer treatment time with the drug.
In conclusion, this compound inhibits growth of cells from
tumours of epithelial cell origin. The mechanism of action of
this growth inhibition is not understood at this time. Interac-
tion with estrogen receptors can be ruled out because it is as
effective on breast cancer cell lines, such as BT-20 and MDA-
MB-231, that do not have estrogen receptors, as it is on lines
that do express functional receptors. Although we cannot
rule out the possibility that a metabolite of Ro 40-8757 may
bind to either the RA or estrogen nuclear receptors, our
current findings suggest that its anti-proliferative activity may
be independent of interaction with these receptors. Clearly,
more work in required to determine the mode of action of
this arotinoid.
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Tanaka for critical reading of the manuscript. This paper is
dedicated to the memory of Dr F. Kaufmann.
References
BOLLAG, W. & HARTMANN, H.R. (1987). Inhibition of rat mammary
carcinogenesis by an arotinoid without a polar end group (Ro
15-0778). Eur. J. Cancer Clin. Oncol., 23, 131-135.
CASTAIGNE, S., CHOMIENNE, C., DANIEL, M.T., BALLERINI, P.,
BERGER, R., FENAUX, P. & DEGOS, L. (1990). All-trans retinoic
acid as a differentiation therapy for acute promyelocytic
leukemia. 1. Clinical results. Blood, 76, 1704-1709.
CHOMIENNE, C., BALLERINI, P., BALITRAND, N., AMAR, M., BER-
NARD, J.F., BOIVIN, P., DANIEL, M.T., BERGER, R., CASTAIGNE,
S. & DEGOS, L. (1989). Retinoic acid therapy for promyelocytic
leukemia. Lancet, ii, 746-747.
CHOMIENNE, C., BALLERINI, P., BALITRAND, N., DANIEL, M.T.,
FENAUX, P., CASTAIGNE, S. & DEGOS, L. (1990). All-trans
retinoic acid in acute promyelocytic leukaemias. 2. In vitro studies
- structure-function relationship. Blood, 76, 1710-1717.
CRETTAZ, M., BARON, A., SIEGENTHALER, G. & HUNZIKER, W.
(1990). Ligand specificities of recombinant retinoic acid receptors
RAR-alpha and RAR-beta. Biochem. J., 272, 391-397.
ELIASON, J., RAMUZ, H. & KAUFMANN, F. (1990a). Human tumor
cells exhibit a high degree of selectivity for stereoisomers of
verapamil and quinidine. Int. J. Cancer, 46, 113-117.
ELIASON, J., TEELMANN, K. & CRETTAZ, M. (1990b). New retinoids
and the future of retinoids in skin cancer. In Retinoids in
Cutaneous Malignancy, Marks, R. (ed) pp. 157-170. Blackwell:
Oxford.
ELIASON, J.F. (1984). Long-term production of hemopoietic pro-
genitors in cultures containing low levels of serum. Exp.
Hematol., 12, 559-567.
ELIASON, J.F., FEKETE, A. & ODARTCHENKO, N. (1984). Improving
techniques for clonogenic assays. Recent Results Cancer Res., 94,
267-275.
ELIASON, J.F., AAPRO, M.S., DECREY, D. & BRINK-PETERSEN, M.
(1985). Non-linearity of colony formation by human tumour cells
from biopsy samples. Br. J. Cancer, 52, 311-318.
HARTMANN, D., TEELMANN, K., ELIASON, J., KAUFMANN, F. &
KLAUS, M. (1992). Ro 40-8757, a novel arotinoid with anti-
cancer activity. In Retinoids, Progress in Research and Clinical
Applications, Livrea, M.A. & Packer, L. (eds) Marcel Dekker,
Inc.: New York.
HONG, W.K., LIPPMAN, S.M. ITRI, L.M., KARP, D.D., LEE, J.S.,
BYERS, R.M., SCHANTZ, S.P., KRAMER, A.M., LOTAN, R.,
PETERS, LJ., DIMERY, I.W., BROWN, B.W. & GOEPFERT, H.
(1990). Prevention of 2nd primary tumors with isotretinoin in
squamous-cell carcinoma of the head and neck. N. Engl. J. Med.,
323, 795-801.
HUANG, M.-E., YE, Y.-C., CHEN, S., CHAI, J.-R., LU, J.X., ZHOA, L.,
GU, L.-j. & WANG, Z.-Y. (1988). Use of all-trans retinoic acid in
the treatment of acute promyelocytic leukaemia. Blood, 72,
567-572.
LIPPMAN, S.M., KESSLER, J.F. & MEYSKENS, F.L. Jr. (1987a).
Retinoids as preventative and therapeutic anticancer agents (Part
I). Cancer Treat. Rep., 71, 391-405.
LIPPMAN, S.M., KESSLER, J.F. & MEYSKENS, F.L. Jr. (1987b).
Retinoids as preventative and therapeutic anticancer agents (Part
II). Cancer Treat. Rep., 71, 493-515.
LIPPMAN, S.M., KAVANAGH, J.J., PAREDES-ESPINOZA, M.,
DELGADILLO-MADRUENO, F., PAREDES-CASILLAS, P., HONG,
W.K., HOLDENER, E. & KRAKOFF, I.H. (1992a). 13-cis-retinoic
acid plus interferon alpha-2a - highly active systemic therapy for
squamous cell carcinoma of the cervix. J. Natl Cancer Inst., 84,
241 -245.
LIPPMAN, S.M., PARKINSON, D.R., ITRI, L.M., WEBER, R.S.,
SCHANTZ, S.P., OTA, D.M., SCHUSTERMAN, M.A., KRAKOFF,
I.H., GUTTERMAN, J.U. & HONG, W.K. (1992b). 13-cis-retinoic
acid and interferon alpha-2a - effective combination therapy for
advanced squamous cell carcinoma of the skin. J. Natl Cancer
Inst., 84, 235-241.1298 J.F. ELIASON et al.
PLUMB, J.A., MILROY, R. & KAYE, S.B. (1989). Effects of the pH
dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide-formazan absorption on chemosensitivity deter-
mined by a novel tetrazolium-based assay. Cancer Res., 49,
4435-4440.
TEELMANN, K. & BOLLAG, W. (1988). Therapeutic effect of the
arotinoid Ro 15-0778 on chemically induced rat mammary car-
cinoma. Eur. J. Cancer Clin. Oncol., 24, 1205-1209.
WARRELL, R.P., FRANKEL, S.R., MILLER, W.H., SCHEINBERG, D.A.,
ITRI, L.M., HITTELMAN, W.N., VYAS, R., ANDREEFF, M.,
TAFURI, A., JAKUBOWSKI, A., GABRILOVE, J., GORDON, M.S. &
DMITROVSKY, E. (1991). Differentiation therapy of acute pro-
myelocytic leukemia with Tretinoin (all-trans-retinoic acid). N.
Engl. J. Med., 324, 1385-1393.